Program
ibrutinib
Also written as “Ibrutinib”, “PCI-32765” and “PCI-32765 (Ibrutinib)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, Large B-Cell, Diffuse · Multiple Myeloma, led by 5 companies.
Drug pageIbrutinib: every studyMany companies study it; this page follows only the 74 they lead. All 264 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 364 open or running | phase 4since Jun 14, 2017 | May 14, 2012 | Dec 31, 2026phase 3 · NCT01804686 |
| AbbVieits history only | 341 open or running | phase 4since Jun 5, 2017 | Feb 20, 2009 | May 10, 2027phase 4 · NCT03229200 |
| Novartisits history only | 21 open or running | phase 2since May 21, 2019 | Mar 13, 2019 | Jun 30, 2027phase 2 · NCT03960840 |
| BeOne Medicinesits history only | 10 open or running | phase 3since Feb 7, 2017 | Feb 7, 2017 | none ahead |
| Oncternal Therapeutics | 10 open or running | phase 3since Jun 9, 2022 | Jun 9, 2022 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Oncternal Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2022First study: phase 3 study in Lymphoma, Mantle-CellFirst studyNCT05431179
TargetBeta
“An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
The one study Oncternal Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05431179Lymphoma, Mantle-Cell | 3 | Withdrawn | Nov 2026 | 0 |
How it is read
Names in the registry
- “Ibrutinib”, 49 entries
- “PCI-32765”, 10 entries
- “ibrutinib”, 6 entries
- “PCI-32765 (Ibrutinib)”, 2 entries
- “SNX-5422 plus ibrutinib”, 2 entries
Codes read as this program: PCI32765.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 23 studies
- Lymphoma, Mantle-Cell, 8 studies
- Waldenstrom Macroglobulinemia, 5 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Multiple Myeloma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.